Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 41 | 2023 | 3143 | 5.230 |
Why?
|
Kidney Neoplasms | 42 | 2023 | 4262 | 4.670 |
Why?
|
Carcinoma, Transitional Cell | 13 | 2024 | 808 | 3.820 |
Why?
|
Urinary Bladder Neoplasms | 14 | 2024 | 2245 | 2.390 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 21 | 2023 | 11524 | 1.730 |
Why?
|
Urologic Neoplasms | 7 | 2021 | 318 | 1.710 |
Why?
|
Immunoconjugates | 4 | 2023 | 901 | 1.530 |
Why?
|
Urogenital Neoplasms | 2 | 2020 | 137 | 1.290 |
Why?
|
Penile Neoplasms | 2 | 2021 | 160 | 1.290 |
Why?
|
Anilides | 6 | 2022 | 408 | 1.180 |
Why?
|
Immunotherapy | 10 | 2021 | 4445 | 0.750 |
Why?
|
Urinary Tract | 1 | 2024 | 309 | 0.740 |
Why?
|
Camptothecin | 1 | 2023 | 576 | 0.730 |
Why?
|
Antibodies, Monoclonal | 6 | 2023 | 9274 | 0.670 |
Why?
|
Pyridines | 6 | 2022 | 2825 | 0.630 |
Why?
|
Nephrectomy | 3 | 2022 | 1050 | 0.600 |
Why?
|
Bone Diseases | 1 | 2020 | 416 | 0.570 |
Why?
|
Testicular Neoplasms | 2 | 2019 | 804 | 0.540 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2021 | 4034 | 0.480 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 501 | 0.470 |
Why?
|
Bone Density Conservation Agents | 1 | 2020 | 773 | 0.450 |
Why?
|
Radiotherapy | 1 | 2019 | 1533 | 0.420 |
Why?
|
Medical Oncology | 1 | 2023 | 2265 | 0.410 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2924 | 0.400 |
Why?
|
Neoplasm Metastasis | 8 | 2022 | 4851 | 0.350 |
Why?
|
Humans | 82 | 2024 | 744343 | 0.350 |
Why?
|
Arabinonucleosides | 1 | 2009 | 35 | 0.340 |
Why?
|
Adenine Nucleotides | 1 | 2009 | 121 | 0.340 |
Why?
|
Buttocks | 1 | 2009 | 110 | 0.330 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13695 | 0.320 |
Why?
|
Sarcoma | 1 | 2019 | 1897 | 0.310 |
Why?
|
Lymph Nodes | 1 | 2019 | 3474 | 0.310 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 222 | 0.300 |
Why?
|
Neoplasm Staging | 7 | 2021 | 11031 | 0.290 |
Why?
|
Protein Kinase Inhibitors | 4 | 2023 | 5535 | 0.290 |
Why?
|
Aneurysm, False | 1 | 2009 | 276 | 0.270 |
Why?
|
Aged, 80 and over | 18 | 2023 | 57776 | 0.270 |
Why?
|
Male | 47 | 2024 | 350118 | 0.270 |
Why?
|
Tissue and Organ Harvesting | 1 | 2009 | 369 | 0.270 |
Why?
|
Adenocarcinoma | 2 | 2022 | 6364 | 0.260 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2009 | 640 | 0.260 |
Why?
|
Rare Diseases | 2 | 2020 | 553 | 0.250 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 407 | 0.250 |
Why?
|
Fatigue | 2 | 2022 | 1531 | 0.240 |
Why?
|
Middle Aged | 33 | 2023 | 213383 | 0.240 |
Why?
|
Cyclophosphamide | 4 | 2021 | 2242 | 0.240 |
Why?
|
Cell Adhesion Molecules | 2 | 2021 | 1602 | 0.240 |
Why?
|
Doxorubicin | 4 | 2021 | 2234 | 0.230 |
Why?
|
Vinblastine | 2 | 2021 | 502 | 0.220 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 7913 | 0.210 |
Why?
|
Phenylthiohydantoin | 2 | 2022 | 193 | 0.210 |
Why?
|
Salvage Therapy | 1 | 2009 | 1275 | 0.210 |
Why?
|
Aged | 29 | 2024 | 163280 | 0.210 |
Why?
|
Brain Neoplasms | 2 | 2022 | 8863 | 0.200 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2023 | 3508 | 0.200 |
Why?
|
Nutrition Disorders | 1 | 2022 | 211 | 0.200 |
Why?
|
Benzoxazoles | 1 | 2022 | 77 | 0.200 |
Why?
|
Organoplatinum Compounds | 2 | 2019 | 408 | 0.190 |
Why?
|
Bone Marrow Cells | 1 | 2009 | 2513 | 0.190 |
Why?
|
Cisplatin | 3 | 2021 | 1662 | 0.190 |
Why?
|
Chorionic Gonadotropin | 1 | 2023 | 477 | 0.190 |
Why?
|
Prostatic Neoplasms | 5 | 2023 | 11124 | 0.190 |
Why?
|
Methotrexate | 3 | 2023 | 1727 | 0.190 |
Why?
|
Platinum | 1 | 2022 | 233 | 0.180 |
Why?
|
Deoxycytidine | 2 | 2021 | 826 | 0.180 |
Why?
|
Georgia | 1 | 2020 | 186 | 0.180 |
Why?
|
Prognosis | 8 | 2022 | 29063 | 0.180 |
Why?
|
Cystectomy | 2 | 2022 | 686 | 0.180 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 252 | 0.180 |
Why?
|
Genetic Counseling | 1 | 2023 | 600 | 0.180 |
Why?
|
Adult | 25 | 2023 | 214055 | 0.180 |
Why?
|
Treatment Outcome | 13 | 2024 | 63114 | 0.180 |
Why?
|
5'-Nucleotidase | 1 | 2020 | 160 | 0.170 |
Why?
|
Endocrine System Diseases | 1 | 2021 | 248 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 315 | 0.170 |
Why?
|
Angiogenesis Inhibitors | 4 | 2023 | 2038 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 212 | 0.170 |
Why?
|
Nitriles | 2 | 2022 | 956 | 0.170 |
Why?
|
Kidney Pelvis | 1 | 2019 | 188 | 0.160 |
Why?
|
Retrospective Studies | 20 | 2022 | 77449 | 0.160 |
Why?
|
Thyroid Diseases | 1 | 2022 | 379 | 0.160 |
Why?
|
Benzamides | 2 | 2022 | 1379 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2022 | 8428 | 0.160 |
Why?
|
Leucovorin | 1 | 2019 | 628 | 0.150 |
Why?
|
Combined Modality Therapy | 4 | 2022 | 8642 | 0.150 |
Why?
|
Female | 30 | 2023 | 380194 | 0.150 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 627 | 0.150 |
Why?
|
Exanthema | 1 | 2021 | 501 | 0.150 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 1681 | 0.150 |
Why?
|
Androgen Antagonists | 2 | 2023 | 1377 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 636 | 0.140 |
Why?
|
Obesity | 1 | 2019 | 12745 | 0.140 |
Why?
|
Quality of Life | 3 | 2023 | 12804 | 0.140 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11366 | 0.130 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.130 |
Why?
|
Autoantibodies | 1 | 2024 | 2035 | 0.130 |
Why?
|
Neck | 1 | 2019 | 697 | 0.130 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3586 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1348 | 0.120 |
Why?
|
Fluorouracil | 1 | 2019 | 1619 | 0.120 |
Why?
|
Eligibility Determination | 1 | 2018 | 403 | 0.120 |
Why?
|
Neutrophils | 4 | 2022 | 3719 | 0.120 |
Why?
|
Tumor Burden | 1 | 2020 | 1915 | 0.120 |
Why?
|
Oligopeptides | 1 | 2019 | 1189 | 0.120 |
Why?
|
Lymphocytes | 2 | 2022 | 2617 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2170 | 0.120 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 2728 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2022 | 1524 | 0.110 |
Why?
|
Gastrointestinal Diseases | 1 | 2021 | 1170 | 0.110 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1788 | 0.110 |
Why?
|
Forecasting | 2 | 2019 | 2951 | 0.110 |
Why?
|
Breast Neoplasms, Male | 1 | 2014 | 210 | 0.110 |
Why?
|
Anemia | 1 | 2022 | 1506 | 0.110 |
Why?
|
Young Adult | 9 | 2021 | 56430 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 738 | 0.110 |
Why?
|
Immunologic Factors | 1 | 2021 | 1580 | 0.100 |
Why?
|
Pyrazoles | 1 | 2022 | 1972 | 0.100 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2727 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2022 | 4479 | 0.090 |
Why?
|
Prospective Studies | 4 | 2024 | 53288 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1671 | 0.090 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4149 | 0.090 |
Why?
|
Survival Rate | 3 | 2020 | 12788 | 0.090 |
Why?
|
Patient Selection | 2 | 2019 | 4215 | 0.090 |
Why?
|
Pyrimidines | 1 | 2022 | 2942 | 0.090 |
Why?
|
Idarubicin | 1 | 2009 | 62 | 0.090 |
Why?
|
Carcinoma | 1 | 2021 | 2375 | 0.090 |
Why?
|
Filgrastim | 1 | 2009 | 133 | 0.080 |
Why?
|
Mitoxantrone | 1 | 2009 | 152 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1972 | 0.080 |
Why?
|
Disease-Free Survival | 4 | 2021 | 6895 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1457 | 0.080 |
Why?
|
Biopsy | 2 | 2019 | 6756 | 0.080 |
Why?
|
Vidarabine | 1 | 2009 | 345 | 0.080 |
Why?
|
Drug Evaluation | 1 | 2009 | 647 | 0.080 |
Why?
|
Etoposide | 1 | 2009 | 641 | 0.080 |
Why?
|
Survival Analysis | 5 | 2021 | 10252 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.070 |
Why?
|
Cytarabine | 1 | 2009 | 692 | 0.070 |
Why?
|
Vincristine | 1 | 2009 | 1039 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2018 | 1587 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2023 | 39050 | 0.070 |
Why?
|
Cell Line, Tumor | 1 | 2023 | 16689 | 0.070 |
Why?
|
Pain | 1 | 2022 | 4986 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13284 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2009 | 648 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2021 | 3479 | 0.070 |
Why?
|
Dementia | 1 | 2019 | 2518 | 0.060 |
Why?
|
Genomics | 1 | 2021 | 5720 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2009 | 1850 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13408 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12959 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40075 | 0.060 |
Why?
|
Androgens | 2 | 2023 | 1281 | 0.060 |
Why?
|
Remission Induction | 1 | 2009 | 2386 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6538 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5221 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5319 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.050 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 182 | 0.050 |
Why?
|
Glutaminase | 1 | 2022 | 35 | 0.050 |
Why?
|
United States | 2 | 2020 | 69872 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7279 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 29786 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2023 | 275 | 0.050 |
Why?
|
Dexamethasone | 1 | 2009 | 1951 | 0.050 |
Why?
|
Genealogy and Heraldry | 1 | 2021 | 28 | 0.050 |
Why?
|
Body Mass Index | 1 | 2019 | 12720 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7181 | 0.050 |
Why?
|
Glutamates | 1 | 2022 | 398 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2014 | 10943 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 339 | 0.050 |
Why?
|
Androstenes | 1 | 2022 | 170 | 0.050 |
Why?
|
Vaccinia virus | 1 | 2022 | 349 | 0.050 |
Why?
|
Postoperative Complications | 1 | 2022 | 15295 | 0.040 |
Why?
|
Glutamine | 1 | 2022 | 578 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2020 | 434 | 0.040 |
Why?
|
Penetrance | 1 | 2021 | 381 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9438 | 0.040 |
Why?
|
Reoperation | 1 | 2009 | 4201 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6622 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 376 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 892 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3597 | 0.040 |
Why?
|
Urothelium | 1 | 2021 | 277 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 371 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 552 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 794 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 610 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 890 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 449 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 841 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 705 | 0.040 |
Why?
|
Tissue Extracts | 1 | 2017 | 135 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 793 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 759 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13102 | 0.040 |
Why?
|
Recurrence | 1 | 2009 | 8340 | 0.040 |
Why?
|
Muscle, Smooth | 1 | 2021 | 934 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2023 | 1149 | 0.040 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1988 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20129 | 0.030 |
Why?
|
Hospital Costs | 1 | 2022 | 985 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2018 | 684 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1003 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 987 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1038 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1518 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 3913 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2021 | 1172 | 0.030 |
Why?
|
Amyloidosis | 1 | 2001 | 795 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1660 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1496 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2018 | 1588 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12354 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 21683 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3616 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 895 | 0.030 |
Why?
|
Creatinine | 1 | 2018 | 1919 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 35421 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2703 | 0.020 |
Why?
|
Animals | 2 | 2022 | 168757 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2009 | 5442 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3461 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 2849 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2001 | 2149 | 0.020 |
Why?
|
Artifacts | 1 | 2018 | 1904 | 0.020 |
Why?
|
Cohort Studies | 3 | 2020 | 40561 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 12026 | 0.020 |
Why?
|
Anticoagulants | 1 | 2022 | 4599 | 0.020 |
Why?
|
Paclitaxel | 1 | 2014 | 1708 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 20822 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5078 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2024 | 7880 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7722 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4933 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5655 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8324 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2001 | 3712 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11483 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 9959 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9648 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 72290 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 85781 | 0.010 |
Why?
|
Pulse Therapy, Drug | 1 | 2001 | 35 | 0.010 |
Why?
|
Serum Amyloid A Protein | 1 | 2001 | 121 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12208 | 0.010 |
Why?
|
Depression | 1 | 2019 | 7766 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17446 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2001 | 1420 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 41006 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23403 | 0.010 |
Why?
|
Child | 1 | 2021 | 77709 | 0.010 |
Why?
|